Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Net Income: 2019-2025

Historic Net Income for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$41.3 million.

  • Allogene Therapeutics' Net Income rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
  • Per Allogene Therapeutics' latest filing, its Net Income stood at -$41.3 million for Q3 2025, which was up 18.82% from -$50.9 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Net Income ranged from a high of $1.9 million in Q4 2021 and a low of -$97.0 million during Q1 2023.
  • In the last 3 years, Allogene Therapeutics' Net Income had a median value of -$64.1 million in 2024 and averaged -$65.0 million.
  • In the last 5 years, Allogene Therapeutics' Net Income soared by 102.76% in 2021 and then plummeted by 5,046.54% in 2022.
  • Over the past 5 years, Allogene Therapeutics' Net Income (Quarterly) stood at $1.9 million in 2021, then tumbled by 5,046.54% to -$93.6 million in 2022, then grew by 15.80% to -$78.8 million in 2023, then rose by 27.02% to -$57.5 million in 2024, then soared by 36.60% to -$41.3 million in 2025.
  • Its last three reported values are -$41.3 million in Q3 2025, -$50.9 million for Q2 2025, and -$59.8 million during Q1 2025.